Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00179
|
|||||
| Drug Name |
L-proline
|
|||||
| Synonyms |
(-)-(S)-Proline; (-)-2-Pyrrolidinecarboxylic acid; (-)-Proline; (-)-Proline (S)-2-Carboxypyrrolidine; (2S)-pyrrolidine-2-carboxylic acid; (L)-PROLINE; (S)-2-Carboxypyrrolidine; (S)-2-Pyrrolidinecarboxylic acid; (S)-Proline; (S)-Pyrrolidine-2-carboxylic acid; 2-pyrrolidinecarboxylic acid; CB 1707; Carboxypyrrolidine; H-Pro-OH; L-(-)-Proline; L-(2,3-3H)Proline; L-Prolin; L-Proline (JAN); L-Proline, labeled with carbon-14; L-Proline-15N; L-Pyrrolidine-2-carboxylic acid; L-alpha-Pyrrolidinecarboxylic acid; PRO (IUPACabbreviation); Pro; Prolina; Prolina [Spanish]; Proline; Proline (USP); Proline (VAN); Proline [USAN:INN]; Prolinum; Prolinum [Latin]
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Dietary shortage [ICD11:5B7Z] | Approved | [1] | |||
| Therapeutic Class |
Dietary supplement
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C5H9NO2
|
|||||
| Canonical SMILES |
C1CC(NC1)C(=O)O
|
|||||
| InChI |
InChI=1S/C5H9NO2/c7-5(8)4-2-1-3-6-4/h4,6H,1-3H2,(H,7,8)/t4-/m0/s1
|
|||||
| InChIKey |
ONIBWKKTOPOVIA-BYPYZUCNSA-N
|
|||||
| CAS Number |
CAS 147-85-3
|
|||||
| Pharmaceutical Properties | Molecular Weight | 115.13 | Topological Polar Surface Area | 49.3 | ||
| Heavy Atom Count | 8 | Rotatable Bond Count | 1 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 3 | |||
| XLogP |
-2.5
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10248984
,10508477
,14710669
,15146482
,15194368
,17435868
,24882005
,24887885
,24887886
,24898097
,24898677
,24898986
,24901637
,24902491
,3135874
,3448
,41102174
,4253464
,46223069
,46504839
,46506858
,49856395
,50108816
,57288676
,57346151
,57652885
,57652886
,57654568
,608065
,6436528
,6436535
,6436537
,77943168
,7847103
,7887166
,7890050
,81044534
,81067296
,8144250
,838056
,841800
,85164895
,85182322
,85201946
,87574669
,92298421
,92710581
,96021916
,96100167
,99206182
|
|||||
| ChEBI ID |
ChEBI:17203
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BGT1 | Transporter Info | Na(+)/Cl(-) betaine/GABA transporter | Substrate | [2] | |
| LAT2 | Transporter Info | L-type amino acid transporter 2 | Substrate | [3] | ||
| PAT1 | Transporter Info | Proton-coupled amino acid transporter 1 | Substrate | [4] | ||
| PAT4 | Transporter Info | Proton-coupled amino acid transporter 4 | Substrate | [5] | ||
| PROT | Transporter Info | Sodium-dependent proline transporter | Substrate | [6] | ||
| References | ||||||
| 1 | L-proline was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Interpreting metabolomic profiles using unbiased pathway models. PLoS Comput Biol. 2010 Feb 26;6(2):e1000692. | |||||
| 3 | The Transporter Classification Database (TCDB): recent advances. Nucleic Acids Res. 2016 Jan 4;44(D1):D372-9. (ID: 2.A.3.8.20) | |||||
| 4 | PAT1 (SLC36A1) shows nuclear localization and affects growth of smooth muscle cells from rats. Am J Physiol Endocrinol Metab. 2014 Jan 1;306(1):E65-74. | |||||
| 5 | SLC36A4 (hPAT4) is a high affinity amino acid transporter when expressed in Xenopus laevis oocytes. J Biol Chem. 2011 Jan 28;286(4):2455-60. | |||||
| 6 | A new association between polymorphisms of the SLC6A7 gene in the chromosome 5q31-32 region and asthma. J Hum Genet. 2010 Jun;55(6):358-65. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.